ClinicalTrials.gg
CompletedNCT02684760Updated Jun 16, 2016

Bioavailability Study Of PF-06651600 In Healthy Subjects

A Phase 1 interventional study of PF-06651600 in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-16.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Inflammatory Bowel Diseases by Pfizer — none open to participants now, none under way, none of them phase 3. Inflammatory Bowel Diseases · Pfizer.

Enrollment
8th of 11
14 · median 44
Started
2016
the only one that year
Phase 1
7 of 15
none open now
Registered
7th of 15
by date

Among the 15 studies in Inflammatory Bowel Diseases by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 7 in phase 1, and was the 7th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

None of the 15 studies in Inflammatory Bowel Diseases by Pfizer is open now. The open studies under Inflammatory Bowel Diseases, anywhere →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Inflammatory Bowel Diseases by Pfizer as a file.
02

Study summary

PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test the bioavailability of a solid dose formulation of PF-06651600 compared to an oral solution formulation under fasting conditions and the effect of a high fat meal on the bioavailability of the solid dose formulation of PF-06651600 in healthy subjects. Safety and tolerability of the tablet and oral solution formulations of PF-06651600 will be assessed under fasting and fed conditions.

03

Conditions studied

  • Healthy

Keywords

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be of non-child bearing potential.
  • of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  • Prior history of chicken pox.
  • Evidence of personally signed and dated document.
  • Willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
  • Screening blood pressure >140/90 mm Hg.
  • Screening laboratory abnormalities as defined by the protocol.
  • Unwilling or unable to comply with the Lifestyle Guidelines as defined by the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Cohort 1: PF-06651600

    Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.

    Drug: PF-06651600

  • Experimental
    Cohort 2: PF-06651600

    Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.

    Drug: PF-06651600

  • Experimental
    Cohort 3: PF-06651600

    Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.

    Drug: PF-06651600

  • Experimental
    Cohort 4: PF-06651600

    Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.

    Drug: PF-06651600

  • Experimental
    Cohort 5: PF-06651600

    Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.

    Drug: PF-06651600

  • Experimental
    Cohort 6: PF-06651600

    Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.

    Drug: PF-06651600

Interventions

  • PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-06651600

    Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06651600

    Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose

  3. Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600

    Time to Reach Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose

Secondary outcomes

  1. Plasma Decay Half Life (t1/2) for PF-06651600

    Plasma Decay Half-Life (t1/2)

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose

  2. Time to Reach Maximum Concentration (Tmax) for PF-06651600

    Time to Reach Maximum Concentration (Tmax)

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose

07

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, 1070, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2016
First posted
Feb 18, 2016
Start
Feb 2016
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Jun 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02684760
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 18, 2016
Start date
Feb 2016
Primary completion
May 2016
Completion
May 2016
Last update
Jun 16, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion